<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5149525</article-id><article-id pub-id-type="doi">10.3389/fimmu.2016.00586</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The Capricious Nature of Bacterial Pathogens: Phasevarions and Vaccine Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Aimee</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/312029"/></contrib><contrib contrib-type="author"><name><surname>Atack</surname><given-names>John M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/246688"/></contrib><contrib contrib-type="author"><name><surname>Jennings</surname><given-names>Michael P.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Seib</surname><given-names>Kate L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/311696"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Institute for Glycomics, Griffith University</institution>, <addr-line>Gold Coast, QLD</addr-line>, <country>Australia</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Lee Mark Wetzler, Boston University School of Medicine, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Sanjay Ram, University of Massachusetts Medical Center, USA; Josep Casades&#x000fa;s, Universidad de Sevilla, Spain</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Kate L. Seib, <email>k.seib@griffith.edu.au</email></corresp><fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Immunotherapies and Vaccines, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>7</volume><elocation-id>586</elocation-id><history><date date-type="received"><day>09</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Tan, Atack, Jennings and Seib.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Tan, Atack, Jennings and Seib</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Infectious diseases are a leading cause of morbidity and mortality worldwide, and vaccines are one of the most successful and cost-effective tools for disease prevention. One of the key considerations for rational vaccine development is the selection of appropriate antigens. Antigens must induce a protective immune response, and this response should be directed to stably expressed antigens so the target microbe can always be recognized by the immune system. Antigens with variable expression, due to environmental signals or phase variation (i.e., high frequency, random switching of expression), are not ideal vaccine candidates because variable expression could lead to immune evasion. Phase variation is often mediated by the presence of highly mutagenic simple tandem DNA repeats, and genes containing such sequences can be easily identified, and their use as vaccine antigens reconsidered. Recent research has identified phase variably expressed DNA methyltransferases that act as global epigenetic regulators. These phase-variable regulons, known as phasevarions, are associated with altered virulence phenotypes and/or expression of vaccine candidates. As such, genes encoding candidate vaccine antigens that have no obvious mechanism of phase variation may be subject to indirect, epigenetic control as part of a phasevarion. Bioinformatic and experimental studies are required to elucidate the distribution and mechanism of action of these DNA methyltransferases, and most importantly, whether they mediate epigenetic regulation of potential and current vaccine candidates. This process is essential to define the stably expressed antigen target profile of bacterial pathogens and thereby facilitate efficient, rational selection of vaccine antigens.</p></abstract><kwd-group><kwd>phase variation</kwd><kwd>vaccine</kwd><kwd>DNA methyltransferase</kwd><kwd>DNA modification enzyme</kwd><kwd>gene expression</kwd><kwd>epigenetics</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">National Health and Medical Research Council<named-content content-type="fundref-id">10.13039/501100000925</named-content></funding-source><award-id rid="cn01">2163530, 1045235, 1099279, 1071659</award-id></award-group><award-group><funding-source id="cn02">Garnett Passe and Rodney Williams Memorial Foundation<named-content content-type="fundref-id">10.13039/501100003354</named-content></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="2"/><equation-count count="0"/><ref-count count="77"/><page-count count="9"/><word-count count="6817"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Infectious diseases are a leading cause of morbidity and mortality worldwide. An estimated 23% of all deaths and 52% of deaths in children under the age of 5&#x02009;years are caused by pathogenic microorganisms (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Over the past two centuries, many vaccines have been developed that aim to prime the host immune system and protect against disease. Consequently, the morbidity and mortality of many diseases have been significantly reduced, such as polio (<xref rid="B3" ref-type="bibr">3</xref>), or even eradicated, such as small pox (<xref rid="B4" ref-type="bibr">4</xref>). Vaccination is often considered one of the greatest triumphs of medical science (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>To date, vaccines are available against 26 pathogens; with at least a further 24 vaccines in the development pipeline (<xref rid="B6" ref-type="bibr">6</xref>). The manufacture and composition of these vaccines varies significantly&#x02009;(<xref rid="B7" ref-type="bibr">7</xref>): from killed-whole cell or virus vaccines [e.g., Salk&#x02019;s original polio vaccine (<xref rid="B8" ref-type="bibr">8</xref>)] and live attenuated vaccines [e.g., the measles, mumps, and rubella vaccine (<xref rid="B9" ref-type="bibr">9</xref>)], to &#x0201c;rationally designed&#x0201d; vaccines, which are subunit formulations specifically developed against selected cellular targets [e.g., the polysaccharide capsule-based pneumococcal conjugate vaccines (<xref rid="B10" ref-type="bibr">10</xref>) and the multivalent recombinant protein-based serogroup B meningococcal vaccine (<xref rid="B11" ref-type="bibr">11</xref>)]. The majority of available vaccines induce antibody-mediated protective immunity and target microorganisms and antigens that have little or no antigenic diversity or variability. Unfortunately, development of vaccines has been more difficult for pathogens that are antigenically diverse, as well as those that cannot be cultured in the laboratory, lack suitable animal models of infection, and/or those that are controlled by mucosal or T cell-dependent immune responses. There is an increasing need for the development of rationally designed vaccines for these pathogens, which has been facilitated by improvements in molecular biology techniques (e.g., DNA sequencing and manipulation; protein and carbohydrate purification; and chemical conjugation methods for production of multivalent vaccines) and increased understanding of pathogen biology, host&#x02013;pathogen interactions, and the requirements for immunogenicity (e.g., immune correlates of protection, and the adjuvants required to elicit this protection) (<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>).</p><p>The era of &#x0201c;omics&#x0201d; and &#x0201c;big data&#x0201d; projects has unleashed a wealth of information for bacterial vaccine development, facilitating the ability to rapidly select potential vaccine antigens from genome and proteome analyses (<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>). However, antigens with variable expression, due to environmental signals or phase variation (i.e., high frequency, random switching of expression), possess inbuilt immune evasion capacity and do not make ideal vaccine candidates. Phase variation is often mediated by the presence of highly mutagenic simple tandem DNA repeats [also known as simple sequence repeats (SSRs)], and genes with these sequence features need to be identified so that can be discounted as vaccine antigens. However, recent research has identified phase variably expressed DNA methyltransferases that act as epigenetic regulators in many bacterial pathogens (<xref rid="B18" ref-type="bibr">18</xref>). These global epigenetic regulators, called phasevarions, can switch expression of candidate vaccine antigens that heretofore have been assumed to be stably expressed.</p><p>In this review, we provide an overview of key aspects that are important during antigen selection for pathogenic bacteria and focus on the impact of phasevarions on vaccine development.</p></sec><sec id="S2"><title>Key Considerations for Vaccine Antigen Selection</title><p>For rationally designed, subunit vaccines to succeed, the selection of appropriate vaccine antigens is critical. Key features of vaccine antigens include (1) immunogenicity (i.e., the ability to elicit an immune response), (2) the ability to induce protection (i.e., the ability of the elicited immune response to prevent proliferation and/or the induction of pathology by the pathogen), and (3) conservation (i.e., the presence and sequence similarity between many/all strains of the pathogen). However, the stable expression of antigens during infection is also a critical factor in antigen selection that is often overlooked.</p><p>Several &#x0201c;omics&#x0201d; approaches are now routinely used to perform systems-based screening of potential antigens, such as genome-based reverse vaccinology, proteomics, transcriptomics, glycomics, and metabolomics (<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>). These approaches allow high throughput identification of the potential antigens of a pathogen. The subsequent analysis of antigen conservation is a relatively straightforward process and has been assisted by the increasing availability of genomes, driven by decreases in sequencing costs (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Sequence availability has also made it possible to assess antigenic drift (change by accumulation of mutations) and shift (complete replacement of antigens), both of which must be taken into account to select stable and effective vaccine antigens (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>).</p><p>Investigation of whether the target antigen is actually expressed by the pathogen during infection <italic>in vivo</italic> is a more complex task, due to regulation by environmental signals and the potential for expression to be influenced by stochastic mechanisms. The transcription and translation of cellular factors are often contingent on environmental signals (e.g., tissue tropism, pH, and temperature) and cellular conditions (e.g., cell cycle) (<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>). For example, for pathogens such as <italic>Escherichia coli</italic> and other enteric pathogens, entry to the site of infection induces the expression of a different antigen repertoire (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>) that is triggered by diverse environmental or host signals such as pH (<xref rid="B31" ref-type="bibr">31</xref>) and temperature (<xref rid="B32" ref-type="bibr">32</xref>). While methods exist that allow the identification of expressed RNA (transcriptome) or protein (proteome) content under selected conditions, data collected often only represent a single physiological state that does not always reflect conditions found in the host. Accordingly, it is important to understand when and how cellular factors are expressed, to ensure that the target antigen is expressed during infection and in the same location (i.e., during mucosal or systemic infection) as the immune response elicited by the vaccine.</p></sec><sec id="S3"><title>Antigen Expression and the Complication of Phase Variation</title><p>Phase variation is defined as the high frequency, reversible ON/OFF, or graded switching of gene expression, which is mediated through either genetic [e.g., due to variations in the number of simple tandem DNA repeats, or genome rearrangements (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>)] or epigenetic [e.g., <italic>via</italic> deoxyadenosine methylase (Dam) (<xref rid="B35" ref-type="bibr">35</xref>)] mechanisms at individual promoters. Many antigens in bacterial pathogens are phase variably expressed. For most phase-variable genes, switching occurs randomly during genome replication, and thus antigen expression is impossible to predict. Consequently, phase-variable components are not ideal vaccine targets since cells that have low, or no, expression of the target antigen may be able to evade the immune system (Figure <xref ref-type="fig" rid="F1">1</xref>A).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Phase variation and immune evasion</bold>. <bold>(A)</bold> For a phase-variable outer-membrane protein, slipped strand mispairing and changes in DNA sequence repeats in the gene during genome replication lead to ON/OFF expression of the encoded protein (blue). Antibodies to this antigen will not be effective if the protein has phased varied OFF. It is typically easy to predict phase-variable expression of these proteins due to the presence of DNA repeats (simple sequence repeat) in the coding region of the gene. <bold>(B)</bold>&#x02009;In phasevarions, phase-variable expression of a DNA methyltransferase causes genome-wide changes in DNA methylation, and expression differences in multiple genes due to epigenetic regulation. If these genes encode antigenic proteins/vaccine candidates, then methylation-dependent loss of expression (red protein) or reduced expression (purple protein) can lead to immune evasion as antibodies lose efficacy. However, due to the epigenetic nature of the phase-variable regulation, it is difficult to predict which proteins will have altered expression.</p></caption><graphic xlink:href="fimmu-07-00586-g001"/></fig><p>Many phase-variable genes can be identified bioinformatically, as the two main phase variation mechanisms, slipped strand mispairing and genome inversions, are well understood (<xref rid="B36" ref-type="bibr">36</xref>). Genes that are variable by slipped strand mispairing can be identified by the presence of multiple, tandem DNA repeats in the upstream or coding region of a gene. Slipped strand mispairing in DNA repeats causes loss or gain of repeats units, leading to frameshift mutations (ON/OFF switching) if located in the coding region, or altered expression levels if located within a promoter or operator region. In the case of genome inversions and recombination mediated mechanisms, phase-variable genes can be identified by the presence of various genetic markers such as recombinases, inverted sequence repeats, cryptic domains, and/or <italic>via</italic> genome comparisons for local reorganization (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>). Bioinformatic searches have been used successfully to identify numerous phase-variable genes in a variety of bacterial pathogens, such as <italic>Neisseria meningitidis</italic> (<xref rid="B38" ref-type="bibr">38</xref>&#x02013;<xref rid="B41" ref-type="bibr">41</xref>), <italic>Neisseria gonorrhoeae</italic> (<xref rid="B42" ref-type="bibr">42</xref>), <italic>Campylobacter jejuni</italic> (<xref rid="B43" ref-type="bibr">43</xref>), <italic>Helicobacter pylori</italic> (<xref rid="B44" ref-type="bibr">44</xref>), and <italic>Haemophilus influenzae</italic> (<xref rid="B45" ref-type="bibr">45</xref>); and these genes are typically excluded from further screening of vaccine candidates. It is interesting to note that NadA, present in the meningococcal serogroup B vaccine (4CMenB, Bexsero), is phase variable. However, the variable expression of NadA is complex and was not easily identifiable <italic>in silico</italic>; the tandem repeats are distally located upstream of the <italic>nadA</italic> promoter and regulation involves both stochastic and classical mechanisms of gene regulation (<xref rid="B46" ref-type="bibr">46</xref>&#x02013;<xref rid="B48" ref-type="bibr">48</xref>).</p><p>The DNA methyltransferase Dam is one of the best studied examples of epigenetic regulation in bacteria. While Dam itself is not phase variable or regulated, it is involved in phase variation of specific virulence genes in <italic>E. coli</italic> and <italic>Salmonella</italic>, such as <italic>pap</italic> (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>) and <italic>agn43</italic> (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). Dam is not believed to serve as a common transcriptional regulatory mechanism (<xref rid="B35" ref-type="bibr">35</xref>). Rather, competition between Dam and a particular DNA-binding regulatory protein provides opportunities for competitive stochastic switches that alter gene expression at specific target sites [reviewed in Ref. (<xref rid="B35" ref-type="bibr">35</xref>)].</p></sec><sec id="S4"><title>Epigenetic Regulation of Antigens <italic>via</italic> Phase-Variable DNA Methyltransferases</title><p>Phase-variable DNA methyltransferases, that act as global epigenetic regulators, have been identified in a number of pathogenic bacteria and add another layer of complexity to the process of antigen selection. Phase variation of these DNA methyltransferases results in coordinated, differential methylation of the entire genome in the DNA methyltransferases ON versus OFF variants. This leads to altered expression of a set of genes that is called a phasevarion, for <italic>phase-vari</italic>able regul<italic>on</italic> (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>B). Phasevarions exert a pleiotropic effect and are associated with variable expression of proteins from diverse functional categories, such as metabolic processes, nutrient acquisition, stress responses, and virulence, as well controlling the variable expression of vaccine candidates. Phasevarions have been characterized in numerous pathogenic bacterial species, including <italic>H. influenzae</italic> (<xref rid="B54" ref-type="bibr">54</xref>&#x02013;<xref rid="B56" ref-type="bibr">56</xref>); the pathogenic <italic>Neisseria</italic> (<xref rid="B57" ref-type="bibr">57</xref>&#x02013;<xref rid="B59" ref-type="bibr">59</xref>); <italic>H. pylori</italic> (<xref rid="B60" ref-type="bibr">60</xref>), <italic>C. jejuni</italic> (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B61" ref-type="bibr">61</xref>), <italic>Moraxella catarrhalis</italic> (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>), and <italic>Streptococcus pneumoniae</italic> (<xref rid="B64" ref-type="bibr">64</xref>) (see Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Phase-variable DNA methyltransferases</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Restriction&#x02013;modification type</th><th valign="top" align="left" rowspan="1" colspan="1">DNA methyltransferase gene</th><th valign="top" align="left" rowspan="1" colspan="1">Species</th><th valign="top" align="left" rowspan="1" colspan="1">Mechanism of phase variation</th><th valign="top" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1">NgoAV (<italic>hsdS<sub>ngoAV</sub></italic>)</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Neisseria gonorrhoeae</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref> of <italic>hsdSNgoAV1</italic> (poly-G repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B65" ref-type="bibr">65</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1">SpnD39III (SpnD39IIIA-FP)</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Streptococcus pneumoniae</italic></td><td align="left" valign="top" rowspan="1" colspan="1">Recombination<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref> generates six potential <italic>hsdS</italic> genes (inverted repeat sequences)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B64" ref-type="bibr">64</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>hsd1</italic> and <italic>hsd2</italic> loci</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Mycoplasma pulmonis</italic></td><td align="left" valign="top" rowspan="1" colspan="1">Recombination between two <italic>hsd</italic> loci generates eight (observed) allele combinations (<italic>vip</italic> and <italic>hrs</italic> sequences)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B66" ref-type="bibr">66</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IIS</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>cj0031</italic></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Campylobacter jejuni</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM of <italic>cj0031</italic> (poly-G repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B61" ref-type="bibr">61</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Putative II</td><td align="left" valign="top" rowspan="1" colspan="1">HpyAIV</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Helicobacter pylori</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM of M.Hpy.AIV (poly-A repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B67" ref-type="bibr">67</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>mod</italic> (HP1407)</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>H. pylori</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM of <italic>res</italic> (and downstream <italic>mod</italic>) (poly-C repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B68" ref-type="bibr">68</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>mod</italic></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Pasteurella haemolytica</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM of <italic>mod</italic> (CACAG repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B69" ref-type="bibr">69</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA</italic></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Haemophilus influenzae, Neisseria meningitidis, N.&#x02009;gonorrhoeae</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM of <italic>modA</italic> (AGCC or AGTC repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B54" ref-type="bibr">54</xref>&#x02013;<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B70" ref-type="bibr">70</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>modB</italic> (<italic>ngoAXmod</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>N. gonorrhoeae, N. meningitidis</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM of <italic>modB</italic> (CCCAA or GCCAA repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>modD</italic></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>N. meningitidis, Neisseria lactamica, Neisseria mucosa, Neisseria cinerea, Neisseria polysaccharea</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM of <italic>modD</italic> (CCGAA repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B57" ref-type="bibr">57</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>modH</italic> (formerly <italic>modC</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>H. pylori</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM of <italic>modH</italic> expression (poly-G repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B60" ref-type="bibr">60</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>modM</italic></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Moraxella catarrhalis</italic></td><td align="left" valign="top" rowspan="1" colspan="1">SSM of <italic>modM</italic> expression (CAAC repeats)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1"><p><italic><sup>a</sup>Slipped strand mispairing (SSM) causes frameshift mutation, altering either the DNA target specificity (type I); or the expression (ON/OFF switching) of the gene indicated. The phase-variable DNA repeat sequence is indicated in brackets</italic>.</p></fn><fn id="tfn2"><p><italic><sup>b</sup>Genome recombination or rearrangement of domains, generating the number of alleles indicated. The sequence motifs mediating recombination are indicated in brackets</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><bold>Phenotypes and phasevarions associated with phase-variable DNA methyltransferases</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Allele and methylation site<xref ref-type="table-fn" rid="tfn3"><sup>a</sup></xref></th><th valign="top" align="left" rowspan="1" colspan="1">Species (strain)</th><th valign="top" align="left" rowspan="1" colspan="1">Phenotypes<xref ref-type="table-fn" rid="tfn4"><sup>b</sup></xref></th><th valign="top" align="left" rowspan="1" colspan="1">Phasevarion analysis<xref ref-type="table-fn" rid="tfn4"><sup>b</sup></xref></th><th valign="top" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA1</italic></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Haemophilus influenzae</italic><break/>RdKW20</td><td align="left" valign="top" rowspan="1" colspan="1">Increased resistance to heat shock</td><td align="left" valign="top" rowspan="1" colspan="1">Microarray: increased expression of cysteine and glutamate/aspartate transport; heme binding; and outer-membrane protein (<italic>opa</italic>). Decreased expression of heat shock and chaperone proteins (<italic>dnaJK, groEL, groES, htpG</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B53" ref-type="bibr">53</xref>&#x02013;<xref rid="B55" ref-type="bibr">55</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA2</italic><break/>5&#x02032;-CCGA<sup>Me</sup><underline>A</underline>-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>H. influenzae</italic><break/>723</td><td align="left" valign="top" rowspan="1" colspan="1">Increased sensitivity to ampicillin; increased biofilm formation; selection for ON <italic>in vivo</italic> (chinchilla infection model)</td><td align="left" valign="top" rowspan="1" colspan="1">iTRAQ: decreased expression of heme utilization (HxuB, HxuC1, HemR), OMP6, and transferring binding protein 1<break/>Microarray: increased expression of iron permeases (<italic>hitAB, yfeACD</italic>) and heme utilization proteins (<italic>hxuAB</italic>), and anaerobic respiration genes</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B56" ref-type="bibr">56</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA4</italic><break/>5&#x02032;-CG<sup>Me</sup><underline>A</underline>G-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>H. influenzae</italic><break/>C486</td><td align="left" valign="top" rowspan="1" colspan="1">Increased survival in opsonophagocytic killing assays</td><td align="left" valign="top" rowspan="1" colspan="1">iTRAQ: OMP P2</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B56" ref-type="bibr">56</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA5</italic><break/>5&#x02032;-AC<sup>Me</sup><underline>A</underline>GC-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>H. influenzae</italic><break/>477</td><td align="left" valign="top" rowspan="1" colspan="1">Increased resistance to erythromycin</td><td align="left" valign="top" rowspan="1" colspan="1">iTRAQ: OMP P5</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B56" ref-type="bibr">56</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA10</italic><break/>5&#x02032;-CCT<sup>Me</sup><underline>A</underline>C-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>H. influenzae</italic><break/>R2866</td><td align="left" valign="top" rowspan="1" colspan="1">Increased resistance to gentamicin</td><td align="left" valign="top" rowspan="1" colspan="1">iTRAQ: OMP P5, P6</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B56" ref-type="bibr">56</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA11</italic><break/>5&#x02032;-CGY<sup>Me</sup><underline>A</underline>G-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Neisseria meningitidis</italic><break/>MC58</td><td align="left" valign="top" rowspan="1" colspan="1">Phenotype: increased antibiotic sensitivity</td><td align="left" valign="top" rowspan="1" colspan="1">Microarray: increased expression of lactoferrin binding proteins <italic>lbpA</italic> and <italic>lbpB</italic> (potential meningococcal vaccine candidate) and other outer-membrane proteins. Reduced expression of ribosomal proteins. Altered expression of DNA repair, energy metabolism, LPS biosynthesis, and other virulence associated genes</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA12</italic><break/>5&#x02032;-AC<sup>Me</sup><underline>A</underline>CC-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>N. meningitidis</italic><break/>B6116/77</td><td align="left" valign="top" rowspan="1" colspan="1">Increased antibiotic sensitivity</td><td align="left" valign="top" rowspan="1" colspan="1">Microarray: increased expression of succinate dehydrogenase operon, <italic>frpA-C</italic> related and bacterioferritin B genes</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA12</italic></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Neisseria gonorrhoeae</italic><break/>96D551</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Microarray: reduced expression of <italic>fetA</italic>, ferric enterobactin binding protein and putative enterobactin permease (ABC transporter)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B58" ref-type="bibr">58</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modA13</italic><break/>5&#x02032;-AGA<sup>Me</sup><underline>A</underline>A-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>N. gonorrhoeae</italic><break/>FA1090</td><td align="left" valign="top" rowspan="1" colspan="1">Increased association with primary cervical epithelial cells, but reduced invasion and survival. Decreased biofilm formation and antimicrobial resistance</td><td align="left" valign="top" rowspan="1" colspan="1">Microarray: response to oxidative stress (<italic>metF, metE</italic>; <italic>NGO0554</italic>; <italic>recN</italic>), antimicrobial resistance (<italic>mtrF</italic>), DNA repair (<italic>recN, NGO0318</italic>), and amino acid biosynthesis (<italic>metFE, NGO0340</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B58" ref-type="bibr">58</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modB1</italic> (<italic>ngoAXmod</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>N. gonorrhoeae</italic><break/>FA1090</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased planktonic growth, biofilm formation, and adherence and invasion of human epithelial cells</td><td align="left" valign="top" rowspan="1" colspan="1">Microarray: down-regulation of biofilm-associated genes including pili (<italic>ngo0095-98</italic>), adhesins <italic>mafA, mafB</italic>, and <italic>opaD</italic></td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B73" ref-type="bibr">73</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modD1</italic><break/>5&#x02032;-CC<sup>Me</sup><underline>A</underline>GC-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>N. meningitidis</italic><break/>M0579</td><td align="left" valign="top" rowspan="1" colspan="1">Increased oxidative stress resistance</td><td align="left" valign="top" rowspan="1" colspan="1">Microarray: increased expression of catalase (<italic>katA</italic>) and factors regulated for growth in blood (<italic>glnA, purF, proB</italic>); decrease in cold-shock domain protein, mip-related protein homolog</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B71" ref-type="bibr">71</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modH5</italic></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Helicobacter pylori</italic><break/>P12</td><td align="left" valign="top" rowspan="1" colspan="1">Not reported</td><td align="left" valign="top" rowspan="1" colspan="1">Microarray: increase in <italic>hopG</italic> (potential vaccine candidate). Decrease in motility associated genes <italic>flaA</italic> and HPP12_904 (<italic>fliK</italic> homolog)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B60" ref-type="bibr">60</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>modM2</italic><break/>5&#x02032;-GAR<sup>Me</sup><underline>A</underline>C-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Moraxella catarrhalis</italic><break/>ATCC 25239</td><td align="left" valign="top" rowspan="1" colspan="1">Not reported</td><td align="left" valign="top" rowspan="1" colspan="1">iTRAQ: increase in proteins important in low iron conditions (FbpA, FixC), cell adherence (RpmG, AhcY), and broth growth (LepB, NqrC); decrease in oxidative stress response (GreA, BfrA)</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B62" ref-type="bibr">62</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>SpnD39IIIA</italic><break/>5&#x02032;-CRA<sup>Me</sup><underline>A</underline>N<sub>8</sub>CTG-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Streptococcus pneumoniae</italic><break/>D39</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased carriage rate; selection for allele in mouse blood</td><td align="left" valign="top" rowspan="1" colspan="1">RNASeq: decrease in <italic>blp</italic>, sucrose regulator, and fucose operon; increase in <italic>psaABC, dnaK</italic></td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B64" ref-type="bibr">64</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>SpnD39IIIB</italic><break/>5&#x02032;-CRA<sup>Me</sup><underline>A</underline>N<sub>9</sub>TTC-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>S. pneumoniae</italic><break/>D39</td><td align="left" valign="top" rowspan="1" colspan="1">Non-opaque colonies, higher phagocytosis by RAW 264.7 cells; lower blood bacteremia rates <italic>in vivo</italic></td><td align="left" valign="top" rowspan="1" colspan="1">RNAseq: decrease in capsule, <italic>luxS, dexB</italic></td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B64" ref-type="bibr">64</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>SpnD39IIIE</italic><break/>5&#x02032;-CRA<sup>Me</sup><underline>A</underline>N<sub>8</sub>CTT-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>S. pneumoniae</italic><break/>D39</td><td align="left" valign="top" rowspan="1" colspan="1">Lower bacteremia rates <italic>in vivo</italic></td><td align="left" valign="top" rowspan="1" colspan="1">Not reported</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B64" ref-type="bibr">64</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>SpnD39IIIF</italic><break/>5&#x02032;-C<sup>Me</sup><underline>A</underline>CN<sub>7</sub>CTT-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>S. pneumoniae</italic><break/>D39</td><td align="left" valign="top" rowspan="1" colspan="1">Lower bacteremia rates <italic>in vivo</italic></td><td align="left" valign="top" rowspan="1" colspan="1">Not reported</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B64" ref-type="bibr">64</xref>)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>cj0031</italic><break/>5&#x02032;-CCYG<sup>Me</sup><underline>A</underline>-3&#x02032;</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Campylobacter jejuni</italic><break/>NCTC11168</td><td align="left" valign="top" rowspan="1" colspan="1">Enhanced adhesion and invasion of epithelial cells; increased biofilm formation; and increased phage restriction ability. ON strains are selected for <italic>in vivo</italic> (chicken model)</td><td align="left" valign="top" rowspan="1" colspan="1">Not reported</td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B61" ref-type="bibr">61</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="tfn3"><p><italic><sup>a</sup>Where available, the methylation site has been indicated by <sup>Me</sup> preceding the methylated residue (underlined)</italic>.</p></fn><fn id="tfn4"><p><italic><sup>b</sup>Unless otherwise specified, the phenotype and phasevarion changes described are increased when the DNA methyltransferase is in phase ON versus OFF. The method used for phasevarion analysis and examples of genes regulated are given</italic>.</p></fn></table-wrap-foot></table-wrap><p>Phasevarions present a critical challenge for vaccine development, in that the genes controlled by phase-variable DNA methyltransferases do not have easily identifiable markers to indicate their phase-variable expression &#x02013; these markers are only associated with the DNA methyltransferase and not the genes it regulates. Consequently, these components may be considered as potential vaccine candidates because their expression is erroneously assumed to be stable. This could potentially result in less effective, or completely ineffective, vaccines (Figure <xref ref-type="fig" rid="F1">1</xref>B).</p></sec><sec id="S5"><title>Types of Phase-Variable DNA Methyltransferases</title><p>Phase-variable DNA methyltransferases have been described that are associated with all three major types of restriction&#x02013;modification (R&#x02013;M) systems (Figure <xref ref-type="fig" rid="F2">2</xref>A; Table <xref ref-type="table" rid="T1">1</xref>). In type I R&#x02013;M systems, the specificity of the DNA methyltransferase is dictated by a specificity subunit (HsdS). Phase variation is typically mediated by this locus, either by slipped strand mispairing [as with the NgoAV system of <italic>N. gonorrhoeae</italic> (<xref rid="B65" ref-type="bibr">65</xref>)] or by genome rearrangements of the <italic>hsdS</italic> subunit domains [as with the SpnD39III system of <italic>S. pneumoniae</italic> (<xref rid="B64" ref-type="bibr">64</xref>)]. In the SpnD39III system, genomic rearrangements result in recombination of one of two possible <italic>hsdS</italic> domain 1 sequences (TRD1.1 and TRD1.2) with one of three possible <italic>hsdS</italic> domain 2 sequences (TRD2.1, 2.2, and 2.3), which can result in the generation of six different <italic>hsdS</italic> alleles (SpnIIIA to SpnIIIF), producing six different HsdS specificity proteins (<xref rid="B64" ref-type="bibr">64</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>B). Accordingly, the SpnIII methyltransferase has six possible DNA specificities, each of which regulates expression of a distinct set of genes. While an individual cell expresses only one allele of each DNA methyltransferase at any particular time, populations of bacteria could express different mixtures of alleles.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Phase-variable DNA methyltransferases</bold>. <bold>(A)</bold> The three main types of restriction&#x02013;methylation (R&#x02013;M) systems: type I consists of separate restriction (R), methyltransferase (M), and specificity (S) components, encoded by <italic>hsdR, hsdM</italic>, and <italic>hsdS</italic> genes, respectively. For restriction to occur, a pentameric R<sub>2</sub>M<sub>2</sub>S complex must form, but methylation can occur independently through a trimeric M<sub>2</sub>S complex. The HsdS subunits dictate the DNA sequences that are restricted and methylated. Type II systems are encoded by individual genes, often located separately on the chromosome. The resulting restriction (R) and methyltransferase (M) enzymes recognize and act independently upon the same DNA motif. Type III systems consist of colocalized <italic>mod</italic> [modification; encoding a methyltransferase, Mod (M)] and <italic>res</italic> [restriction; encoding a restriction enzyme, Res (R)] genes. Res proteins require Mod to restrict DNA (R<sub>2</sub>M<sub>2</sub>), but Mod enzymes are active as stand-alone methyltransferases (M<sub>2</sub>). <bold>(B)</bold> Phase variation of type I R&#x02013;M systems <italic>via</italic> recombination between expressed (<italic>hsdS</italic>) and silent (<italic>hsdS'</italic>) specificity genes. Each <italic>hsdS</italic> gene contains two target recognition domains (TRDs), each contributing half to the sequence recognized by the HsdS protein. Shuffling of each TRD <italic>via</italic> recombination between homologous inverted repeats (gray at 5&#x02032; end, yellow in center) leads to four possible combinations, and therefore, four different methyltransferase specificities in this example. <bold>(C)</bold> Phase variation of type III R&#x02013;M systems <italic>via</italic> slipped strand mispairing (SSM) of simple sequence repeats in the open reading frame of the <italic>mod</italic> genes. Loss or gain of a repeat unit leads to variation in the open reading frame and either expression of a functional Mod protein (Mod ON), or transcriptional termination through the presence of a premature stop codon (Mod OFF).</p></caption><graphic xlink:href="fimmu-07-00586-g002"/></fig><p>In type II and III R&#x02013;M systems, the DNA methyltransferases are independent proteins that dictate the specificity of the methylation site, and phase variation is typically mediated by slipped strand mispairing of SSRs in the coding sequence of the DNA methyltransferase (<italic>mod</italic>) gene (Table <xref ref-type="table" rid="T1">1</xref>). Changes in repeat number cause frameshift mutations and switching of Mod protein expression between &#x0201c;ON&#x0201d; (expressed) or &#x0201c;OFF&#x0201d; (not expressed) states (Figure <xref ref-type="fig" rid="F2">2</xref>C). The type III Mod proteins are the most extensively studied (Table <xref ref-type="table" rid="T1">1</xref>), and multiple allelic variants exist for each system, as determined by sequence differences in the DNA recognition domain responsible for methyltransferase specificity (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B71" ref-type="bibr">71</xref>). For example, 21 <italic>modA</italic> alleles (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B70" ref-type="bibr">70</xref>), 6 <italic>modB</italic> alleles (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B74" ref-type="bibr">74</xref>), and 7 <italic>modD</italic> alleles (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B74" ref-type="bibr">74</xref>) have been identified to date. Unlike the type I systems described above, switching between alleles by genome rearrangement within a strain has not been reported and only one allele is present in a given strain. However, horizontal transfer of allele DNA recognition domains occurs and is postulated to generate novel DNA methyltransferase alleles over time (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B76" ref-type="bibr">76</xref>).</p></sec><sec id="S6"><title>Phasevarions and Vaccine Development</title><p>The challenge for vaccine development is to determine whether specific antigens are members of phasevarions prior to investing time in developing them as vaccine candidates. Previous studies have identified proposed vaccine candidates in phasevarions, including <italic>hopG</italic> (encoding a major outer-membrane protein) in the <italic>H. pylori</italic> ModH5 phasevarion (<xref rid="B60" ref-type="bibr">60</xref>), <italic>lbp</italic> (encoding lactoferrin binding protein) in the <italic>N. meningitidis</italic> ModA11 phasevarion (<xref rid="B58" ref-type="bibr">58</xref>), HMW adhesins in the <italic>H. influenzae</italic> ModA2, ModA4, and ModA5 phasevarions (<xref rid="B56" ref-type="bibr">56</xref>), and capsule in the <italic>S. pneumoniae</italic> SpnIIID39B phasevarion (<xref rid="B64" ref-type="bibr">64</xref>) (Table <xref ref-type="table" rid="T2">2</xref>). Furthermore, many phasevarions are associated with virulence, which may be of concern as virulence determinants are often targets of vaccine development. For example, the ModA11 and ModA12 phasevarions in <italic>N. meningitidis</italic> (<xref rid="B72" ref-type="bibr">72</xref>), ModA13 and M.NgoAX in <italic>N. gonorrhoeae</italic> (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B73" ref-type="bibr">73</xref>), and ModA2, ModA5, and ModA10 in <italic>H. influenzae</italic> (<xref rid="B56" ref-type="bibr">56</xref>) all affect antimicrobial susceptibility. ModA2 (<italic>H. influenzae</italic>), ModA13 (<italic>N. gonorrhoeae</italic>) (<xref rid="B58" ref-type="bibr">58</xref>), and <italic>cj0031</italic> (<italic>C. jejuni</italic>) (<xref rid="B61" ref-type="bibr">61</xref>) alter biofilm formation. <italic>N. meningitidis</italic> ModD1 can increase oxidative stress resistance and regulate factors important for growth and survival in blood (<xref rid="B57" ref-type="bibr">57</xref>). Different pneumococcal SpnIII alleles are associated with causing different phenotypes in <italic>S. pneumoniae</italic>, such as nasopharyngeal colonization (SpnIIIB) or bacteremia (SpnIIIA) (<xref rid="B64" ref-type="bibr">64</xref>) (Table <xref ref-type="table" rid="T2">2</xref>).</p><p>Consequently, when considering the impact of phasevarions on vaccine development, it is important to know which allele(s) are present in the bacterial species, as well as the distribution of these alleles &#x02013; that is, whether certain alleles predominate among the pathogenic strains that require targeting by the vaccine. Previous studies have used PCR and Sanger sequencing methods to identify and determine alleles (<xref rid="B55" ref-type="bibr">55</xref>&#x02013;<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B62" ref-type="bibr">62</xref>); however, the increasing ease and lowered costs of full genome sequencing will enable the simple identification of phase-variable methyltransferases in broader, larger sample panels, as well as the identification of new or novel systems. For example, the availability of a large database of meningococcal genome sequences has recently been used to help survey the <italic>mod</italic> allele repertoire in over 1,600 isolates (<xref rid="B74" ref-type="bibr">74</xref>).</p><p>A bigger challenge lies in defining the proteins regulated within each phasevarion, as this must be determined experimentally. This has previously been accomplished by custom transcriptomic microarray analysis (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B60" ref-type="bibr">60</xref>), but is being supplanted by next generation sequencing techniques [namely RNAseq, as in Ref. (<xref rid="B64" ref-type="bibr">64</xref>)] and proteomic analyses [e.g., iTRAQ, as in Ref. (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B62" ref-type="bibr">62</xref>)]. RNAseq allows the visualization of the full transcriptomic response to DNA methyltransferase phase variation, including differences in transcription of RNA genes (such as tRNAs) and non-coding RNAs (such as siRNAs and other regulatory RNAs). RNAseq will also provide valuable information about transcriptional start sites and upstream regulatory sequences for genes in the phasevarion, and possible transcription kinetics around methylation sites, enabling detailed mechanistic studies to be performed. In contrast, proteomic analyses will definitively identify the protein antigens differentially expressed by phasevarions under the conditions tested. This may differ from the transcriptomic data as RNA expression does not always correlate to protein translation, and so future studies should analyze expression data using multiple techniques in order to identify all members of each phasevarion. This will be invaluable for examining the actual changes in antigen levels and how this may affect vaccines.</p><p>The identification and analysis of genes controlled by phasevarions need to be carried out under conditions relevant to infection. This is because epigenetic regulation <italic>via</italic> DNA methylation is typically a multistep process, with DNA methylation affecting the action of regulatory proteins involved in transcription, rather than acting on transcriptional machinery itself [reviewed recently in Ref. (<xref rid="B77" ref-type="bibr">77</xref>)]. As such, conditions tested must be biologically relevant and allow these regulatory proteins to be active, in order to observe epigenetic regulation. This has been demonstrated by microarray analysis of the ModA11 phasevarion, where iron-limiting conditions were necessary to identify phasevarion members (mimicking iron limitation in the host, compared with standard laboratory culture conditions) (<xref rid="B58" ref-type="bibr">58</xref>). Unfortunately, the specific conditions that permit the full expression of the phasevarion can be difficult to determine, and bacteria should be grown under biologically relevant conditions, or if possible, collected directly from infection sites &#x02013; such as from blood or mucosal surfaces. It is also critical that the whole, or representative, bacterial population is isolated and analyzed during phasevarion studies. This will allow the natural ON/OFF status and ratio of phase-variable DNA methyltransferases in the <italic>in vivo</italic> bacterial population to be understood.</p></sec><sec id="S7"><title>Concluding Remarks</title><p>The development of bacterial vaccines depends on the selection of appropriate antigens. Ideal vaccine antigens are conserved, immunogenic, and protective. They should also be consistently expressed at high enough levels during infection to be targeted by the immune system. Transient and arbitrary expression makes antigen targeting by the immune system difficult and could lead to immune evasion <italic>via</italic> escape of a subpopulation that do not express the antigen. For this reason, phase-variable antigens do not make ideal vaccine candidates.</p><p>Phase-variable regulators complicate the prediction of stably expressed antigens, as the regulated genes within a phasevarion lack overt markers that indicate potential random switching of expression. While phasevarions have been studied in a range of pathogenic bacteria, important questions remain regarding allele variability, distribution, and regulatory mechanisms. More detailed understanding of these factors will help to elucidate the full complement of phase-variable genes in human pathogens for which vaccine development has been problematic, and help facilitate robust antigen selection for rational vaccine design in the future.</p></sec><sec id="S8"><title>Author Contributions</title><p>All the authors contributed to drafting and revising the manuscript and approved the final manuscript.</p></sec><sec id="S9"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><sec id="S10"><title>Funding</title><p>This study was funded by Australian National Health and Medical Research Council (NHMRC) (Project Grants 2163530 and Career Development Fellowship to KS; Project Grant 1099279 to KS and JA; Program Grant 1071659 to MJ); Garnett Passe and Rodney Williams Memorial Foundation Research Training Fellowship to AT.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Oza</surname><given-names>S</given-names></name><name><surname>Hogan</surname><given-names>D</given-names></name><name><surname>Perin</surname><given-names>J</given-names></name><name><surname>Rudan</surname><given-names>I</given-names></name><name><surname>Lawn</surname><given-names>JE</given-names></name><etal/></person-group>
<article-title>Global, regional, and national causes of child mortality in 20-2013, with projections to inform post-2015 priorities: an updated systematic analysis</article-title>. <source>Lancet</source> (<year>2015</year>) <volume>385</volume>(<issue>9966</issue>):<fpage>430</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(14)61698-6</pub-id><pub-id pub-id-type="pmid">25280870</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="webpage"><collab>World Health Organisation</collab>. <source>The Global Burden of Disease (2004 Update)</source> (<year>2004</year>). Available from: <uri xlink:type="simple" xlink:href="http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/">http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/</uri></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cochi</surname><given-names>SL</given-names></name><name><surname>Freeman</surname><given-names>A</given-names></name><name><surname>Guirguis</surname><given-names>S</given-names></name><name><surname>Jafari</surname><given-names>H</given-names></name><name><surname>Aylward</surname><given-names>B</given-names></name></person-group>. <article-title>Global polio eradication initiative: lessons learned and legacy</article-title>. <source>J Infect Dis</source> (<year>2014</year>) <volume>210</volume>(<issue>Suppl 1</issue>):<fpage>S540</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1093/infdis/jiu345</pub-id><?supplied-pmid 25316878?><pub-id pub-id-type="pmid">25316878</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>DA</given-names></name></person-group>
<article-title>The eradication of smallpox &#x02013; an overview of the past, present, and future</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>(<issue>Suppl 4</issue>):<fpage>D7</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.080</pub-id><pub-id pub-id-type="pmid">22188929</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>B</given-names></name></person-group>
<article-title>The contribution of vaccination to global health: past, present and future</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source> (<year>2014</year>) <volume>369</volume>:<fpage>1645</fpage>.</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="book"><collab>World Health Organisation</collab>. <publisher-name>World Health Organisation</publisher-name> (<year>2016</year>). Available from: <uri xlink:type="simple" xlink:href="http://www.who.int/immunization/diseases/en/">http://www.who.int/immunization/diseases/en/</uri></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajj Hussein</surname><given-names>I</given-names></name><name><surname>Chams</surname><given-names>N</given-names></name><name><surname>Chams</surname><given-names>S</given-names></name><name><surname>El Sayegh</surname><given-names>S</given-names></name><name><surname>Badran</surname><given-names>R</given-names></name><name><surname>Raad</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Vaccines through centuries: major cornerstones of global health</article-title>. <source>Front Public Health</source> (<year>2015</year>) <volume>3</volume>:<fpage>269</fpage>.<pub-id pub-id-type="doi">10.3389/fpubh.2015.00269</pub-id><?supplied-pmid 26636066?><pub-id pub-id-type="pmid">26636066</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salk</surname><given-names>JE</given-names></name><name><surname>Krech</surname><given-names>U</given-names></name><name><surname>Youngner</surname><given-names>JS</given-names></name><name><surname>Bennett</surname><given-names>BL</given-names></name><name><surname>Lewis</surname><given-names>LJ</given-names></name><name><surname>Bazeley</surname><given-names>PL</given-names></name></person-group>
<article-title>Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines</article-title>. <source>Am J Public Health Nations Health</source> (<year>1954</year>) <volume>44</volume>(<issue>5</issue>):<fpage>563</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.2105/AJPH.44.5.563</pub-id><pub-id pub-id-type="pmid">13148396</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lievano</surname><given-names>F</given-names></name><name><surname>Galea</surname><given-names>SA</given-names></name><name><surname>Thornton</surname><given-names>M</given-names></name><name><surname>Wiedmann</surname><given-names>RT</given-names></name><name><surname>Manoff</surname><given-names>SB</given-names></name><name><surname>Tran</surname><given-names>TN</given-names></name><etal/></person-group>
<article-title>Measles, mumps, and rubella virus vaccine (M-M-R&#x02122;II): a review of 32 years of clinical and postmarketing experience</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>(<issue>48</issue>):<fpage>6918</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.08.057</pub-id><pub-id pub-id-type="pmid">22959986</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tromp</surname><given-names>KM</given-names></name><name><surname>Campbell</surname><given-names>MW</given-names></name><name><surname>Vazquez</surname><given-names>A</given-names></name></person-group>. <article-title>Recent developments and future directions of pneumococcal vaccine recommendations</article-title>. <source>Clin Ther</source> (<year>2015</year>) <volume>37</volume>(<issue>5</issue>):<fpage>928</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1016/j.clinthera.2015.03.025</pub-id><?supplied-pmid 25913921?><pub-id pub-id-type="pmid">25913921</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>S</given-names></name><name><surname>Principi</surname><given-names>N</given-names></name></person-group>. <article-title>Vaccine profile of 4CMenB: a four-component <italic>Neisseria meningitidis</italic> serogroup B vaccine</article-title>. <source>Expert Rev Vaccines</source> (<year>2014</year>) <volume>13</volume>(<issue>2</issue>):<fpage>193</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="doi">10.1586/14760584.2014.874949</pub-id><?supplied-pmid 24393061?><pub-id pub-id-type="pmid">24393061</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group>
<article-title>Designing tomorrow&#x02019;s vaccines</article-title>. <source>New Engl J Med</source> (<year>2013</year>) <volume>368</volume>(<issue>6</issue>):<fpage>551</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMra1204186</pub-id><pub-id pub-id-type="pmid">23388006</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rueckert</surname><given-names>C</given-names></name><name><surname>Guzman</surname><given-names>CA</given-names></name></person-group>. <article-title>Vaccines: from empirical development to rational design</article-title>. <source>PLoS Pathog</source> (<year>2012</year>) <volume>8</volume>(<issue>11</issue>):<fpage>e1003001</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1003001</pub-id><?supplied-pmid 23144616?><pub-id pub-id-type="pmid">23144616</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delany</surname><given-names>I</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name><name><surname>Seib</surname><given-names>KL</given-names></name></person-group>. <article-title>Vaccines, reverse vaccinology, and bacterial pathogenesis</article-title>. <source>Cold Spring Harb Perspect Med</source> (<year>2013</year>) <volume>3</volume>(<issue>5</issue>):<fpage>a012476</fpage>.<pub-id pub-id-type="doi">10.1101/cshperspect.a012476</pub-id><?supplied-pmid 23637311?><pub-id pub-id-type="pmid">23637311</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinaudo</surname><given-names>CD</given-names></name><name><surname>Telford</surname><given-names>JL</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name><name><surname>Seib</surname><given-names>KL</given-names></name></person-group>. <article-title>Vaccinology in the genome era</article-title>. <source>J Clin Invest</source> (<year>2009</year>) <volume>119</volume>(<issue>9</issue>):<fpage>2515</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1172/JCI38330</pub-id><?supplied-pmid 19729849?><pub-id pub-id-type="pmid">19729849</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rappuoli</surname><given-names>R</given-names></name></person-group>. <article-title>Reverse vaccinology, a genome-based approach to vaccine development</article-title>. <source>Vaccine</source> (<year>2001</year>) <volume>19</volume>(<issue>17&#x02013;19</issue>):<fpage>2688</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/S0264-410X(00)00554-5</pub-id><?supplied-pmid 11257410?><pub-id pub-id-type="pmid">11257410</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamczyk-Poplawska</surname><given-names>M</given-names></name><name><surname>Markowicz</surname><given-names>S</given-names></name><name><surname>Jagusztyn-Krynicka</surname><given-names>EK</given-names></name></person-group>. <article-title>Proteomics for development of vaccine</article-title>. <source>J Proteomics</source> (<year>2011</year>) <volume>74</volume>(<issue>12</issue>):<fpage>2596</fpage>&#x02013;<lpage>616</lpage>.<pub-id pub-id-type="doi">10.1016/j.jprot.2011.01.019</pub-id><?supplied-pmid 21310271?><pub-id pub-id-type="pmid">21310271</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Fox</surname><given-names>KL</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name></person-group>. <article-title>The phasevarion: phase variation of type III DNA methyltransferases controls coordinated switching in multiple genes</article-title>. <source>Nat Rev Microbiol</source> (<year>2010</year>) <volume>8</volume>(<issue>3</issue>):<fpage>196</fpage>&#x02013;<lpage>206</lpage>.<pub-id pub-id-type="doi">10.1038/nrmicro2283</pub-id><?supplied-pmid 20140025?><pub-id pub-id-type="pmid">20140025</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seib</surname><given-names>KL</given-names></name><name><surname>Dougan</surname><given-names>G</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name></person-group>. <article-title>The key role of genomics in modern vaccine and drug design for emerging infectious diseases</article-title>. <source>PLoS Genet</source> (<year>2009</year>) <volume>5</volume>(<issue>10</issue>):<fpage>e1000612</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pgen.1000612</pub-id><?supplied-pmid 19855822?><pub-id pub-id-type="pmid">19855822</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geissner</surname><given-names>A</given-names></name><name><surname>Anish</surname><given-names>C</given-names></name><name><surname>Seeberger</surname><given-names>PH</given-names></name></person-group>. <article-title>Glycan arrays as tools for infectious disease research</article-title>. <source>Curr Opin Chem Biol</source> (<year>2014</year>) <volume>18</volume>:<fpage>38</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1016/j.cbpa.2013.11.013</pub-id><?supplied-pmid 24534751?><pub-id pub-id-type="pmid">24534751</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>C</given-names></name><name><surname>Hammerschmidt</surname><given-names>S</given-names></name></person-group>. <article-title>Exploitation of physiology and metabolomics to identify pneumococcal vaccine candidates</article-title>. <source>Expert Rev Vaccines</source> (<year>2013</year>) <volume>12</volume>(<issue>9</issue>):<fpage>1061</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1586/14760584.2013.824708</pub-id><?supplied-pmid 24053399?><pub-id pub-id-type="pmid">24053399</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Land</surname><given-names>M</given-names></name><name><surname>Hauser</surname><given-names>L</given-names></name><name><surname>Jun</surname><given-names>S-R</given-names></name><name><surname>Nookaew</surname><given-names>I</given-names></name><name><surname>Leuze</surname><given-names>MR</given-names></name><name><surname>Ahn</surname><given-names>T-H</given-names></name><etal/></person-group>
<article-title>Insights from 20 years of bacterial genome sequencing</article-title>. <source>Funct Integr Genomics</source> (<year>2015</year>) <volume>15</volume>(<issue>2</issue>):<fpage>141</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1007/s10142-015-0433-4</pub-id><?supplied-pmid 25722247?><pub-id pub-id-type="pmid">25722247</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentley</surname><given-names>SD</given-names></name><name><surname>Parkhill</surname><given-names>J</given-names></name></person-group>
<article-title>Genomic perspectives on the evolution and spread of bacterial pathogens</article-title>. <source>Proc R Soc Lond B Biol Sci</source> (<year>2015</year>) <volume>282</volume>:<fpage>1821</fpage>.</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrat</surname><given-names>F</given-names></name><name><surname>Flahault</surname><given-names>A</given-names></name></person-group>. <article-title>Influenza vaccine: the challenge of antigenic drift</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>(<issue>39&#x02013;40</issue>):<fpage>6852</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2007.07.027</pub-id><?supplied-pmid 17719149?><pub-id pub-id-type="pmid">17719149</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>PA</given-names></name></person-group>. <article-title>Evolution of norovirus</article-title>. <source>Clin Microbiol Infect</source> (<year>2014</year>) <volume>20</volume>(<issue>8</issue>):<fpage>741</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1111/1469-0691.12746</pub-id><?supplied-pmid 24980204?><pub-id pub-id-type="pmid">24980204</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Browning</surname><given-names>DF</given-names></name><name><surname>Busby</surname><given-names>SJ</given-names></name></person-group>. <article-title>The regulation of bacterial transcription initiation</article-title>. <source>Nat Rev Microbiol</source> (<year>2004</year>) <volume>2</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1038/nrmicro787</pub-id><?supplied-pmid 15035009?><pub-id pub-id-type="pmid">15035009</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buelow</surname><given-names>DR</given-names></name><name><surname>Raivio</surname><given-names>TL</given-names></name></person-group>
<article-title>Three (and more) component regulatory systems &#x02013; auxiliary regulators of bacterial histidine kinases</article-title>. <source>Mol Microbiol</source> (<year>2010</year>) <volume>75</volume>(<issue>3</issue>):<fpage>547</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2958.2009.06982.x</pub-id><pub-id pub-id-type="pmid">19943903</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staron</surname><given-names>A</given-names></name><name><surname>Sofia</surname><given-names>HJ</given-names></name><name><surname>Dietrich</surname><given-names>S</given-names></name><name><surname>Ulrich</surname><given-names>LE</given-names></name><name><surname>Liesegang</surname><given-names>H</given-names></name><name><surname>Mascher</surname><given-names>T</given-names></name></person-group>. <article-title>The third pillar of bacterial signal transduction: classification of the extracytoplasmic function (ECF) sigma factor protein family</article-title>. <source>Mol Microbiol</source> (<year>2009</year>) <volume>74</volume>(<issue>3</issue>):<fpage>557</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2958.2009.06870.x</pub-id><?supplied-pmid 19737356?><pub-id pub-id-type="pmid">19737356</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>SE</given-names></name><name><surname>Winter</surname><given-names>MG</given-names></name><name><surname>Godinez</surname><given-names>I</given-names></name><name><surname>Yang</surname><given-names>H-J</given-names></name><name><surname>R&#x000fc;ssmann</surname><given-names>H</given-names></name><name><surname>Andrews-Polymenis</surname><given-names>HL</given-names></name><etal/></person-group>
<article-title>A rapid change in virulence gene expression during the transition from the intestinal lumen into tissue promotes systemic dissemination of <italic>Salmonella</italic></article-title>. <source>PLoS Pathog</source> (<year>2010</year>) <volume>6</volume>(<issue>8</issue>):<fpage>e1001060</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1001060</pub-id><?supplied-pmid 20808848?><pub-id pub-id-type="pmid">20808848</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Tauschek</surname><given-names>M</given-names></name><name><surname>Hart</surname><given-names>E</given-names></name><name><surname>Hartland</surname><given-names>EL</given-names></name><name><surname>Robins-Browne</surname><given-names>RM</given-names></name></person-group>
<article-title>Virulence regulation in <italic>Citrobacter rodentium</italic>: the art of timing</article-title>. <source>Microb Biotechnol</source> (<year>2009</year>) <volume>3</volume>(<issue>3</issue>):<fpage>259</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1111/j.1751-7915.2009.00114.x</pub-id><pub-id pub-id-type="pmid">21255326</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwan</surname><given-names>WR</given-names></name><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Lenard</surname><given-names>FA</given-names></name><name><surname>Matthews</surname><given-names>BT</given-names></name><name><surname>Beck</surname><given-names>MT</given-names></name></person-group>. <article-title>Osmolarity and pH growth conditions regulate <italic>fim</italic> gene transcription and type 1 pilus expression in uropathogenic <italic>Escherichia coli</italic></article-title>. <source>Infect Immun</source> (<year>2002</year>) <volume>70</volume>(<issue>3</issue>):<fpage>1391</fpage>&#x02013;<lpage>402</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.70.3.1391-1402.2002</pub-id><?supplied-pmid 11854225?><pub-id pub-id-type="pmid">11854225</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gophna</surname><given-names>U</given-names></name><name><surname>Ron</surname><given-names>EZ</given-names></name></person-group>. <article-title>Virulence and the heat shock response</article-title>. <source>Int J Med Microbiol</source> (<year>2003</year>) <volume>292</volume>(<issue>7&#x02013;8</issue>):<fpage>453</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1078/1438-4221-00230</pub-id><?supplied-pmid 12635928?><pub-id pub-id-type="pmid">12635928</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>IR</given-names></name><name><surname>Owen</surname><given-names>P</given-names></name><name><surname>Nataro</surname><given-names>JP</given-names></name></person-group>
<article-title>Molecular switches &#x02013; the on and off of bacterial phase variation</article-title>. <source>Mol Microbiol</source> (<year>1999</year>) <volume>33</volume>(<issue>5</issue>):<fpage>919</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2958.1999.01555.x</pub-id><pub-id pub-id-type="pmid">10476027</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moxon</surname><given-names>R</given-names></name><name><surname>Bayliss</surname><given-names>C</given-names></name><name><surname>Hood</surname><given-names>D</given-names></name></person-group>. <article-title>Bacterial contingency loci: the role of simple sequence DNA repeats in bacterial adaptation</article-title>. <source>Annu Rev Genet</source> (<year>2006</year>) <volume>40</volume>(<issue>1</issue>):<fpage>307</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.genet.40.110405.090442</pub-id><?supplied-pmid 17094739?><pub-id pub-id-type="pmid">17094739</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhikari</surname><given-names>S</given-names></name><name><surname>Curtis</surname><given-names>PD</given-names></name></person-group>
<article-title>DNA methyltransferases and epigenetic regulation in bacteria</article-title>. <source>FEMS Microbiol Rev</source> (<year>2016</year>) <volume>40</volume>(<issue>5</issue>):<fpage>575</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1093/femsre/fuw023</pub-id><pub-id pub-id-type="pmid">27476077</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Woude</surname><given-names>MW</given-names></name><name><surname>B&#x000e4;umler</surname><given-names>AJ</given-names></name></person-group>. <article-title>Phase and antigenic variation in bacteria</article-title>. <source>Clin Microbiol Rev</source> (<year>2004</year>) <volume>17</volume>(<issue>3</issue>):<fpage>581</fpage>&#x02013;<lpage>611</lpage>.<pub-id pub-id-type="doi">10.1128/CMR.17.3.581-611.2004</pub-id><?supplied-pmid 15258095?><pub-id pub-id-type="pmid">15258095</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallet</surname><given-names>B</given-names></name></person-group>. <article-title>Playing Dr Jekyll and Mr Hyde: combined mechanisms of phase variation in bacteria</article-title>. <source>Curr Opin Microbiol</source> (<year>2001</year>) <volume>4</volume>(<issue>5</issue>):<fpage>570</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/S1369-5274(00)00253-8</pub-id><?supplied-pmid 11587935?><pub-id pub-id-type="pmid">11587935</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>van de Ven</surname><given-names>T</given-names></name><name><surname>Mouchel</surname><given-names>N</given-names></name><name><surname>Jeffries</surname><given-names>AC</given-names></name><name><surname>Hood</surname><given-names>DW</given-names></name><name><surname>Moxon</surname><given-names>ER</given-names></name></person-group>. <article-title>Experimentally revised repertoire of putative contingency loci in <italic>Neisseria meningitidis</italic> strain MC58: evidence for a novel mechanism of phase variation</article-title>. <source>Mol Microbiol</source> (<year>2003</year>) <volume>50</volume>(<issue>1</issue>):<fpage>245</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03678.x</pub-id><?supplied-pmid 14507378?><pub-id pub-id-type="pmid">14507378</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Nie</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Characterization of ST-4821 complex, a unique <italic>Neisseria meningitidis</italic> clone</article-title>. <source>Genomics</source> (<year>2008</year>) <volume>91</volume>(<issue>1</issue>):<fpage>78</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1016/j.ygeno.2007.10.004</pub-id><?supplied-pmid 18031983?><pub-id pub-id-type="pmid">18031983</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>NJ</given-names></name><name><surname>Jeffries</surname><given-names>AC</given-names></name><name><surname>Peden</surname><given-names>JF</given-names></name><name><surname>Hood</surname><given-names>DW</given-names></name><name><surname>Tettelin</surname><given-names>H</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Repeat-associated phase variable genes in the complete genome sequence of <italic>Neisseria meningitidis</italic> strain MC58</article-title>. <source>Mol Microbiol</source> (<year>2000</year>) <volume>37</volume>(<issue>1</issue>):<fpage>207</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2958.2000.02000.x</pub-id><?supplied-pmid 10931317?><pub-id pub-id-type="pmid">10931317</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>LAS</given-names></name><name><surname>Butcher</surname><given-names>SA</given-names></name><name><surname>Saunders</surname><given-names>NJ</given-names></name></person-group>. <article-title>Comparative whole-genome analyses reveal over 100 putative phase-variable genes in the pathogenic <italic>Neisseria</italic> spp</article-title>.&#x02009;<source>Microbiology</source> (<year>2001</year>) <volume>147</volume>(<issue>8</issue>):<fpage>2321</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1099/00221287-147-8-2321</pub-id><?supplied-pmid 11496009?><pub-id pub-id-type="pmid">11496009</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>PW</given-names></name><name><surname>Snyder</surname><given-names>LA</given-names></name><name><surname>Saunders</surname><given-names>NJ</given-names></name></person-group>. <article-title>Strain-specific differences in <italic>Neisseria gonorrhoeae</italic> associated with the phase variable gene repertoire</article-title>. <source>BMC Microbiol</source> (<year>2005</year>) <volume>5</volume>:<fpage>21</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2180-5-21</pub-id><?supplied-pmid 15857514?><pub-id pub-id-type="pmid">15857514</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayliss</surname><given-names>CD</given-names></name><name><surname>Bidmos</surname><given-names>FA</given-names></name><name><surname>Anjum</surname><given-names>A</given-names></name><name><surname>Manchev</surname><given-names>VT</given-names></name><name><surname>Richards</surname><given-names>RL</given-names></name><name><surname>Grossier</surname><given-names>J-P</given-names></name><etal/></person-group>
<article-title>Phase variable genes of <italic>Campylobacter jejuni</italic> exhibit high mutation rates and specific mutational patterns but mutability is not the major determinant of population structure during host colonization</article-title>. <source>Nucleic Acids Res</source> (<year>2012</year>) <volume>40</volume>(<issue>13</issue>):<fpage>5876</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gks246</pub-id><pub-id pub-id-type="pmid">22434884</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>NJ</given-names></name><name><surname>Peden</surname><given-names>JF</given-names></name><name><surname>Hood</surname><given-names>DW</given-names></name><name><surname>Moxon</surname><given-names>ER</given-names></name></person-group>. <article-title>Simple sequence repeats in the <italic>Helicobacter pylori</italic> genome</article-title>. <source>Mol Microbiol</source> (<year>1998</year>) <volume>27</volume>(<issue>6</issue>):<fpage>1091</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2958.1998.00768.x</pub-id><?supplied-pmid 9570395?><pub-id pub-id-type="pmid">9570395</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hood</surname><given-names>DW</given-names></name><name><surname>Deadman</surname><given-names>ME</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name><name><surname>Bisercic</surname><given-names>M</given-names></name><name><surname>Fleischmann</surname><given-names>RD</given-names></name><name><surname>Venter</surname><given-names>JC</given-names></name><etal/></person-group>
<article-title>DNA repeats identify novel virulence genes in <italic>Haemophilus influenzae</italic></article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1996</year>) <volume>93</volume>(<issue>20</issue>):<fpage>11121</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.93.20.11121</pub-id><?supplied-pmid 8855319?><pub-id pub-id-type="pmid">8855319</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liguori</surname><given-names>A</given-names></name><name><surname>Malito</surname><given-names>E</given-names></name><name><surname>Lo Surdo</surname><given-names>P</given-names></name><name><surname>Fagnocchi</surname><given-names>L</given-names></name><name><surname>Cantini</surname><given-names>F</given-names></name><name><surname>Haag</surname><given-names>AF</given-names></name><etal/></person-group>
<article-title>Molecular basis of ligand-dependent regulation of NadR, the transcriptional repressor of meningococcal virulence factor NadA</article-title>. <source>PLoS Pathog</source> (<year>2016</year>) <volume>12</volume>(<issue>4</issue>):<fpage>e1005557</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1005557</pub-id><?supplied-pmid 27105075?><pub-id pub-id-type="pmid">27105075</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Makepeace</surname><given-names>K</given-names></name><name><surname>Hill</surname><given-names>SA</given-names></name><name><surname>Hood</surname><given-names>DW</given-names></name><name><surname>Moxon</surname><given-names>ER</given-names></name></person-group>. <article-title>Microsatellite instability regulates transcription factor binding and gene expression</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2005</year>) <volume>102</volume>(<issue>10</issue>):<fpage>3800</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0406805102</pub-id><?supplied-pmid 15728391?><pub-id pub-id-type="pmid">15728391</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metruccio</surname><given-names>MME</given-names></name><name><surname>Pigozzi</surname><given-names>E</given-names></name><name><surname>Roncarati</surname><given-names>D</given-names></name><name><surname>Berlanda Scorza</surname><given-names>F</given-names></name><name><surname>Norais</surname><given-names>N</given-names></name><name><surname>Hill</surname><given-names>SA</given-names></name><etal/></person-group>
<article-title>A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements</article-title>. <source>PLoS Pathog</source> (<year>2009</year>) <volume>5</volume>(<issue>12</issue>):<fpage>e1000710</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1000710</pub-id><?supplied-pmid 20041170?><pub-id pub-id-type="pmid">20041170</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernday</surname><given-names>AD</given-names></name><name><surname>Braaten</surname><given-names>BA</given-names></name><name><surname>Low</surname><given-names>DA</given-names></name></person-group>. <article-title>The mechanism by which DNA adenine methylase and PapI activate the pap epigenetic switch</article-title>. <source>Mol Cell</source> (<year>2003</year>) <volume>12</volume>(<issue>4</issue>):<fpage>947</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/S1097-2765(03)00383-6</pub-id><?supplied-pmid 14580345?><pub-id pub-id-type="pmid">14580345</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Woude</surname><given-names>M</given-names></name><name><surname>Braaten</surname><given-names>B</given-names></name><name><surname>Low</surname><given-names>D</given-names></name></person-group>. <article-title>Epigenetic phase variation of the pap operon in <italic>Escherichia coli</italic></article-title>. <source>Trends Microbiol</source> (<year>1996</year>) <volume>4</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/0966-842X(96)81498-3</pub-id><?supplied-pmid 8824788?><pub-id pub-id-type="pmid">8824788</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>W</given-names></name><name><surname>Van Der Woude</surname><given-names>M</given-names></name></person-group>. <article-title>Phase variation of Ag43 in <italic>Escherichia coli</italic>: Dam-dependent methylation abrogates OxyR binding and OxyR-mediated repression of transcription</article-title>. <source>Mol Microbiol</source> (<year>2000</year>) <volume>35</volume>(<issue>4</issue>):<fpage>877</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2958.2000.01762.x</pub-id><?supplied-pmid 10692164?><pub-id pub-id-type="pmid">10692164</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallecha</surname><given-names>A</given-names></name><name><surname>Munster</surname><given-names>V</given-names></name><name><surname>Correnti</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>T</given-names></name><name><surname>van der Woude</surname><given-names>M</given-names></name></person-group>. <article-title>Dam- and OxyR-dependent phase variation of <italic>agn43</italic>: essential elements and evidence for a new role of DNA methylation</article-title>. <source>J Bacteriol</source> (<year>2002</year>) <volume>184</volume>(<issue>12</issue>):<fpage>3338</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1128/JB.184.12.3338-3347.2002</pub-id><?supplied-pmid 12029051?><pub-id pub-id-type="pmid">12029051</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>KL</given-names></name><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name></person-group>. <article-title>Phase variable type III restriction-modification systems of host-adapted bacterial pathogens</article-title>. <source>Mol Microbiol</source> (<year>2007</year>) <volume>65</volume>(<issue>6</issue>):<fpage>1375</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2958.2007.05873.x</pub-id><?supplied-pmid 17714447?><pub-id pub-id-type="pmid">17714447</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Maguire</surname><given-names>TL</given-names></name><name><surname>Stacey</surname><given-names>KJ</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name></person-group>. <article-title>The phasevarion: a genetic system controlling coordinated, random switching of expression of multiple genes</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2005</year>) <volume>102</volume>(<issue>15</issue>):<fpage>5547</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0501169102</pub-id><?supplied-pmid 15802471?><pub-id pub-id-type="pmid">15802471</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>KL</given-names></name><name><surname>Dowideit</surname><given-names>SJ</given-names></name><name><surname>Erwin</surname><given-names>AL</given-names></name><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name></person-group>. <article-title><italic>Haemophilus influenzae</italic> phasevarions have evolved from type III DNA restriction systems into epigenetic regulators of gene expression</article-title>. <source>Nucleic Acids Res</source> (<year>2007</year>) <volume>35</volume>(<issue>15</issue>):<fpage>5242</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gkm571</pub-id><?supplied-pmid 17675301?><pub-id pub-id-type="pmid">17675301</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atack</surname><given-names>JM</given-names></name><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Fox</surname><given-names>KL</given-names></name><name><surname>Jurcisek</surname><given-names>JA</given-names></name><name><surname>Brockman</surname><given-names>KL</given-names></name><name><surname>Clark</surname><given-names>TA</given-names></name><etal/></person-group>
<article-title>A biphasic epigenetic switch controls immunoevasion, virulence and niche adaptation in non-typeable <italic>Haemophilus influenzae</italic></article-title>. <source>Nat Commun</source> (<year>2015</year>) <volume>6</volume>:<fpage>7828</fpage><pub-id pub-id-type="doi">10.1038/ncomms8828</pub-id><pub-id pub-id-type="pmid">26215614</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seib</surname><given-names>KL</given-names></name><name><surname>Pigozzi</surname><given-names>E</given-names></name><name><surname>Muzzi</surname><given-names>A</given-names></name><name><surname>Gawthorne</surname><given-names>JA</given-names></name><name><surname>Delany</surname><given-names>I</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name><etal/></person-group>
<article-title>A novel epigenetic regulator associated with the hypervirulent <italic>Neisseria meningitidis</italic> clonal complex 41/44</article-title>. <source>FASEB J</source> (<year>2011</year>) <volume>25</volume>(<issue>10</issue>):<fpage>3622</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1096/fj.11-183590</pub-id><?supplied-pmid 21680891?><pub-id pub-id-type="pmid">21680891</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Dowideit</surname><given-names>SJ</given-names></name><name><surname>Edwards</surname><given-names>JL</given-names></name><name><surname>Falsetta</surname><given-names>ML</given-names></name><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Harrison</surname><given-names>OB</given-names></name><etal/></person-group>
<article-title>Phasevarions mediate random switching of gene expression in pathogenic <italic>Neisseria</italic></article-title>. <source>PLoS Pathog</source> (<year>2009</year>) <volume>5</volume>(<issue>4</issue>):<fpage>e1000400</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1000400</pub-id><?supplied-pmid 19390608?><pub-id pub-id-type="pmid">19390608</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamczyk-Poplawska</surname><given-names>M</given-names></name><name><surname>Lower</surname><given-names>M</given-names></name><name><surname>Piekarowicz</surname><given-names>A</given-names></name></person-group>
<article-title>Characterization of the NgoAXP: phase-variable type III restriction-modification system in <italic>Neisseria gonorrhoeae</italic></article-title>. <source>FEMS Microbiol Lett</source> (<year>2009</year>) <volume>300</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1111/j.1574-6968.2009.01760.x</pub-id><pub-id pub-id-type="pmid">19758331</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Gorrell</surname><given-names>RJ</given-names></name><name><surname>Steen</surname><given-names>JA</given-names></name><name><surname>Gawthorne</surname><given-names>JA</given-names></name><name><surname>Kwok</surname><given-names>T</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><etal/></person-group>
<article-title>Phasevarion mediated epigenetic gene regulation in <italic>Helicobacter pylori</italic></article-title>. <source>PLoS One</source> (<year>2011</year>) <volume>6</volume>(<issue>12</issue>):<fpage>e27569</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0027569</pub-id><?supplied-pmid 22162751?><pub-id pub-id-type="pmid">22162751</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anjum</surname><given-names>A</given-names></name><name><surname>Brathwaite</surname><given-names>KJ</given-names></name><name><surname>Aidley</surname><given-names>J</given-names></name><name><surname>Connerton</surname><given-names>PL</given-names></name><name><surname>Cummings</surname><given-names>NJ</given-names></name><name><surname>Parkhill</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Phase variation of a Type IIG restriction-modification enzyme alters site-specific methylation patterns and gene expression in <italic>Campylobacter jejuni</italic> strain NCTC11168</article-title>. <source>Nucleic Acids Res</source> (<year>2016</year>) <volume>44</volume>(<issue>10</issue>):<fpage>4581</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gkw019</pub-id><?supplied-pmid 26786317?><pub-id pub-id-type="pmid">26786317</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blakeway</surname><given-names>LV</given-names></name><name><surname>Power</surname><given-names>PM</given-names></name><name><surname>Jen</surname><given-names>FE</given-names></name><name><surname>Worboys</surname><given-names>SR</given-names></name><name><surname>Boitano</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>TA</given-names></name><etal/></person-group>
<article-title>ModM DNA methyltransferase methylome analysis reveals a potential role for <italic>Moraxella catarrhalis</italic> phasevarions in otitis media</article-title>. <source>FASEB J</source> (<year>2014</year>) <volume>28</volume>(<issue>12</issue>):<fpage>5197</fpage>&#x02013;<lpage>207</lpage>.<pub-id pub-id-type="doi">10.1096/fj.14-256578</pub-id><?supplied-pmid 25183669?><pub-id pub-id-type="pmid">25183669</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seib</surname><given-names>KL</given-names></name><name><surname>Peak</surname><given-names>IR</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name></person-group>. <article-title>Phase variable restriction-modification systems in <italic>Moraxella catarrhalis</italic></article-title>. <source>FEMS Immunol Med Microbiol</source> (<year>2002</year>) <volume>32</volume>(<issue>2</issue>):<fpage>159</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1016/S0928-8244(01)00294-2</pub-id><?supplied-pmid 11821238?><pub-id pub-id-type="pmid">11821238</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manso</surname><given-names>AS</given-names></name><name><surname>Chai</surname><given-names>MH</given-names></name><name><surname>Atack</surname><given-names>JM</given-names></name><name><surname>Furi</surname><given-names>L</given-names></name><name><surname>De Ste Croix</surname><given-names>M</given-names></name><name><surname>Haigh</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>A random six-phase switch regulates pneumococcal virulence via global epigenetic changes</article-title>. <source>Nat Commun</source> (<year>2014</year>) <volume>5</volume>:<fpage>5055</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms6055</pub-id><?supplied-pmid 25268848?><pub-id pub-id-type="pmid">25268848</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamczyk-Poplawska</surname><given-names>M</given-names></name><name><surname>Lower</surname><given-names>M</given-names></name><name><surname>Piekarowicz</surname><given-names>A</given-names></name></person-group>. <article-title>Deletion of one nucleotide within the homonucleotide tract present in the <italic>hsdS</italic> gene alters the DNA sequence specificity of type I restriction-modification system NgoAV</article-title>. <source>J Bacteriol</source> (<year>2011</year>) <volume>193</volume>(<issue>23</issue>):<fpage>6750</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1128/JB.05672-11</pub-id><?supplied-pmid 21984785?><pub-id pub-id-type="pmid">21984785</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dybvig</surname><given-names>K</given-names></name><name><surname>Sitaraman</surname><given-names>R</given-names></name><name><surname>French</surname><given-names>CT</given-names></name></person-group>. <article-title>A family of phase-variable restriction enzymes with differing specificities generated by high-frequency gene rearrangements</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1998</year>) <volume>95</volume>(<issue>23</issue>):<fpage>13923</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.95.23.13923</pub-id><?supplied-pmid 9811902?><pub-id pub-id-type="pmid">9811902</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skoglund</surname><given-names>A</given-names></name><name><surname>Bj&#x000f6;rkholm</surname><given-names>B</given-names></name><name><surname>Nilsson</surname><given-names>C</given-names></name><name><surname>Andersson</surname><given-names>AF</given-names></name><name><surname>Jernberg</surname><given-names>C</given-names></name><name><surname>Schirwitz</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Functional analysis of the M.HpyAIV DNA methyltransferase of <italic>Helicobacter pylori</italic></article-title>. <source>J Bacteriol</source> (<year>2007</year>) <volume>189</volume>(<issue>24</issue>):<fpage>8914</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1128/JB.00108-07</pub-id><?supplied-pmid 17921292?><pub-id pub-id-type="pmid">17921292</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>N</given-names></name><name><surname>Duinsbergen</surname><given-names>D</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name><name><surname>Pot</surname><given-names>RGJ</given-names></name><name><surname>Wiesenekker</surname><given-names>P</given-names></name><name><surname>Penn</surname><given-names>CW</given-names></name><etal/></person-group>
<article-title>Transcriptional phase variation of a Type III restriction-modification system in <italic>Helicobacter pylori</italic></article-title>. <source>J Bacteriol</source> (<year>2002</year>) <volume>184</volume>(<issue>23</issue>):<fpage>6615</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1128/JB.184.23.6615-6624.2002</pub-id><?supplied-pmid 12426350?><pub-id pub-id-type="pmid">12426350</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>KA</given-names></name><name><surname>Lo</surname><given-names>RYC</given-names></name></person-group>. <article-title>Characterization of a CACAG pentanucleotide repeat in <italic>Pasteurella haemolytica</italic> and its possible role in modulation of a novel type III restriction-modification system</article-title>. <source>Nucleic Acids Res</source> (<year>1999</year>) <volume>27</volume>(<issue>6</issue>):<fpage>1505</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1093/nar/27.6.1505</pub-id><?supplied-pmid 10037813?><pub-id pub-id-type="pmid">10037813</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gawthorne</surname><given-names>JA</given-names></name><name><surname>Beatson</surname><given-names>SA</given-names></name><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Fox</surname><given-names>KL</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name></person-group>. <article-title>Origin of the diversity in DNA recognition domains in phasevarion associated modA genes of pathogenic <italic>Neisseria</italic> and <italic>Haemophilus influenzae</italic></article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>(<issue>3</issue>):<fpage>e32337</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0032337</pub-id><?supplied-pmid 22457715?><pub-id pub-id-type="pmid">22457715</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seib</surname><given-names>KL</given-names></name><name><surname>Jen</surname><given-names>FE</given-names></name><name><surname>Tan</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>AL</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Power</surname><given-names>PM</given-names></name><etal/></person-group>
<article-title>Specificity of the ModA11, ModA12 and ModD1 epigenetic regulator N6-adenine DNA methyltransferases of <italic>Neisseria meningitidis</italic></article-title>. <source>Nucleic Acids Res</source> (<year>2015</year>) <volume>43</volume>(<issue>8</issue>):<fpage>4150</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gkv219</pub-id><pub-id pub-id-type="pmid">25845594</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jen</surname><given-names>FE</given-names></name><name><surname>Seib</surname><given-names>KL</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name></person-group>. <article-title>Phasevarions mediate epigenetic regulation of antimicrobial susceptibility in <italic>Neisseria meningitidis</italic></article-title>. <source>Antimicrob Agents Chemother</source> (<year>2014</year>) <volume>58</volume>(<issue>7</issue>):<fpage>4219</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1128/AAC.00004-14</pub-id><?supplied-pmid 24777094?><pub-id pub-id-type="pmid">24777094</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwiatek</surname><given-names>A</given-names></name><name><surname>Mrozek</surname><given-names>A</given-names></name><name><surname>Bacal</surname><given-names>P</given-names></name><name><surname>Piekarowicz</surname><given-names>A</given-names></name><name><surname>Adamczyk-Pop&#x00142;awska</surname><given-names>M</given-names></name></person-group>
<article-title>Type III methyltransferase M.NgoAX from <italic>Neisseria gonorrhoeae</italic> FA1090 regulates biofilm formation and interactions with human cells</article-title>. <source>Front Microbiol</source> (<year>2015</year>) <volume>6</volume>:<fpage>1426</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2015.01426</pub-id><pub-id pub-id-type="pmid">26733970</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>DMC</given-names></name><name><surname>Harrison</surname><given-names>OB</given-names></name><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name><name><surname>Maiden</surname><given-names>MCJ</given-names></name><etal/></person-group>
<article-title>Distribution of the type III DNA methyltransferases modA, modB and modD among <italic>Neisseria meningitidis</italic> genotypes: implications for gene regulation and virulence</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>21015</fpage>.<pub-id pub-id-type="doi">10.1038/srep21015</pub-id><?supplied-pmid 26867950?><pub-id pub-id-type="pmid">26867950</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayliss</surname><given-names>CD</given-names></name><name><surname>Callaghan</surname><given-names>MJ</given-names></name><name><surname>Moxon</surname><given-names>ER</given-names></name></person-group>. <article-title>High allelic diversity in the methyltransferase gene of a phase variable type III restriction-modification system has implications for the fitness of <italic>Haemophilus influenzae</italic></article-title>. <source>Nucleic Acids Res</source> (<year>2006</year>) <volume>34</volume>(<issue>14</issue>):<fpage>4046</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gkl568</pub-id><?supplied-pmid 16914439?><pub-id pub-id-type="pmid">16914439</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>I</given-names></name></person-group>. <article-title>Movement of DNA sequence recognition domains between non-orthologous proteins</article-title>. <source>Nucleic Acids Res</source> (<year>2012</year>) <volume>40</volume>(<issue>18</issue>):<fpage>9218</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gks681</pub-id><?supplied-pmid 22821560?><pub-id pub-id-type="pmid">22821560</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casades&#x000fa;s</surname><given-names>J</given-names></name><name><surname>Low</surname><given-names>DA</given-names></name></person-group>. <article-title>Programmed heterogeneity: epigenetic mechanisms in bacteria</article-title>. <source>J Biol Chem</source> (<year>2013</year>) <volume>288</volume>(<issue>20</issue>):<fpage>13929</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.R113.472274</pub-id><?supplied-pmid 23592777?><pub-id pub-id-type="pmid">23592777</pub-id></mixed-citation></ref></ref-list></back></article>